Oncology News | pharmaphorum

News

Immutep investors spooked by LAG-3 failure in lung cancer

Friday the 13th has turned into a horror story for Immutep, whose share price has collapsed after it abandoned a pivotal trial of its LAG-3 drug efti.

News

NICE says no to Genmab cervical cancer therapy

Genmab's recently approved therapy for relapsed cervical cancer has been turned down for NHS use in initial NICE guidance.

News

BioNTech bigwigs will step down to form new mRNA company

The co-founders of mRNA specialist BioNTech – husband and wife team Uğur Şahin and Özlem Türeci – have said they are leaving to set up a new company.

News

BMS eyes another celmod filing in myeloma after phase 3 win

Bristol Myers Squibb now has positive phase 3 data under its belt for celmod mezigdomide, as it waits for an FDA verdict on lead drug iberdomide.

News

Incyte breaks new ground in anal cancer with EU approval

Incyte claims EU approval for Zynyz as the first systemic therapy for anal cancer, as J&J gets the nod for wider use of Akeega in prostate cancer.

News

Roche's oral SERD flunks phase 3 breast cancer test

Roche's recent run of positive study results with breast cancer candidate giredestrant has come to an end with the failure of the persevERA trial.

Immutep investors spooked by LAG-3 failure in lung cancer

NICE says no to Genmab cervical cancer therapy

BioNTech bigwigs will step down to form new mRNA company

BMS eyes another celmod filing in myeloma after phase 3 win

Incyte breaks new ground in anal cancer with EU approval

Roche's oral SERD flunks phase 3 breast cancer test

ESC26: Isomab safety evidence on blood vessel growth for CAD

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks